Description
Seeking men and women with eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus (food pipe) that may cause difficulty swallowing, for a study of the long-term effect of dupilumab on esophageal function and remodeling.
Overview
Participants in this study will be randomly assigned to get either dipilumab or placebo (looks like the study drug but contains no medicine) for 24 weeks after which all participants will get dipilumab. The participant will take the study drug or placebo by injection once a week. There are six office visits in the first year of the study and then four office visits over the remaining two years of the study.
What we're hoping for
We are studying whether if study drug dupilumab heals scar tissue in the esophagus (food pipe), thus preventing or reversing narrowing of the esophagus over time in adult participants who have eosinophilic esophagitis (EOE).
Additional Information
ClinicalTrials.gov Identifier: NCT06101095